Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

situximab

- PMLiVE

Amsterdam picked to host the European Medicines Agency

But regulator faces a “challenging” relocation project to depart from London

- PMLiVE

Merck pulls Keytruda filing in Europe, despite US approval

Phase II KeyNote-0241 trial results failed to win over the EMA

- PMLiVE

Positive trial results for Janssen’s Symtuza boosts its HIV credentials

The STR provided ‘effective’ and ‘durable’ viral suppression

- PMLiVE

CDC backs GSK’s Shingrix over Merck & Co’s Zostavax

US advisors recommend GSK's shingle vaccine be used instead of Merck's rival product

Janssen’s quest to prevent diseases taking hold

Johan van Hoof, general manager of Janssen Vaccines & Prevention, on 'recalibrating' public understanding of illness

- PMLiVE

Janssen’s quest to prevent diseases taking hold

Johan van Hoof, general manager of Janssen Vaccines & Prevention, on 'recalibrating' public understanding of illness

AstraZeneca AZ

AZ and MSD win FDA priority review for Lynparza in breast cancer

Could become the first PARP inhibitor to be approved in the US for the disease

- PMLiVE

Janssen develops digital tools to help automate clinical trials

iSTEP platform combines mobile tech and smart packaging

- PMLiVE

CHMP recommends Teva’s generic version of Astellas’ Advagraf

Committee backs the drug for transplant rejection prophylaxis

Roche Basel Switzerland

Roche wins CHMP nod for Alecensa licence extensions

Lung cancer monotherapy set for a broader European label

- PMLiVE

Moving times

Continuity and stability are vital when it comes to the EMA's relocation when it leaves London

- PMLiVE

CETP inhibitor class finally dies as Merck abandons anacetrapib

Cholesterol drug fails to “support regulatory filings”

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links